- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastric cancer
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Trifluridine with tipiracil – November 2019
Trifluridine with Tipiracil: Tablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride), Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride); Lonsurf®
Last updated
6 March 2020